Researchers concluded that the GLP-1RA showed no ability to slow disease progression in people living with Parkinson’s ...

Oral semaglutide administered via the RaniPill® HC (RT-116) demonstrated comparable bioavailability, pharmacokinetics and ...

Endometrial cancer (EC) ranks as the second most prevalent gynecologic malignancy globally, with approximately 189,000 new ...

Weight loss drugs, which took the US market by storm, are looking to be a big opportunity for drug makers in India. Several ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance. The approach is especially popular among telemedicine physicians, who ...

Rani Therapeutics (RANI) announced new pharmacokinetic and pharmacodynamic data from a preclinical study evaluating the oral delivery of the ...

Lexaria Bioscience (LEXX) announces that dosing has begun in its fluorescently tagged DehydraTECH-semaglutide rodent biodistribution study. The ...

Obesity is a growing concern worldwide, including in low- and middle-income countries (LMICs). Addressing this issue involves various strategies, including dietary and lifestyle changes, medical ...

KELOWNA, BC / ACCESSWIRE / February 6, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the 'Company' or 'Lexaria'), a global innovator in drug delivery platforms, announces that dosing ...

A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of cardiovascular disease.

Jefferies maintains a Buy rating on JB Pharma citing strong CDMO growth potential and a 34% upside. Know more about it.